Harvard Bioscience (HBIO) Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has reported Current Assets for 17 consecutive years, with $46.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets rose 3.32% year-over-year to $46.5 million in Q2 2026; TTM through Jun 2026 was $46.5 million, a 3.32% increase from a year earlier, with the FY2025 full-year figure at $48.2 million, up 6.89% from the prior year.
• Current Assets was $46.5 million for Q2 2026 at Harvard Bioscience, down from $47.5 million in the prior quarter.
• Over five years, Current Assets peaked at $59.4 million in Q1 2022 and troughed at $43.8 million in Q3 2025.
• A 5-year average of $49.2 million and a median of $48.2 million in 2024 frame the typical range for Current Assets.
• The widest YoY moves for Current Assets: up 20.77% in 2022, down 16.98% in 2022.
• Over 5 years, Current Assets stood at $51.1 million in 2022, then declined by 4.08% to $49.0 million in 2023, then dropped by 8.0% to $45.1 million in 2024, then increased by 6.89% to $48.2 million in 2025, then slipped by 3.65% to $46.5 million in 2026.
• The last three Current Assets figures came in at $46.5 million (Q2 2026), $47.5 million (Q1 2026), and $48.2 million (Q4 2025), per Business Quant data.